Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

A national precision cancer medicine implementation initiative for Norway

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: InPreD allows the diagnosis and assessment of cancer patients where experimental treatment and clinical trial inclusion is an option.


  1. Von Hoff, D. D. et al. J. Clin. Oncol. 28, 4877–4883 (2010).

    Article  Google Scholar 

  2. Jardim, D. L. et al. J. Natl. Cancer Inst. 107, djv253 (2015).

    Article  Google Scholar 

  3. Le Tourneau, C. et al. Lancet Oncol. 16, 1324–1334 (2015).

    Article  Google Scholar 

  4. IMPRESS-Norway. Clinical trial for cancer patients; (2021).

  5. van der Velden, D. L. et al. Nature 574, 127–131 (2019).

    Article  Google Scholar 

  6. van der Wijngaart, H. et al. Clin. Cancer Res. 27, 6106–6114 (2021).

    Article  Google Scholar 

  7. Netherlands Cancer Institute. (2021).

  8. CONNECT. Norwegian Cancer Precision Medicine Implementation Consortium; (2020).

Download references


The authors are grateful for public funding to the precision cancer medicine ecosystem from the Regional Health Authorities for South-Eastern, Western, Middle and Northern Norway, the Norwegian Clinical Treatment Research Programme (KLINBEFORSK), the Norwegian Cancer Society, the Nordic Trial Alliance/NordForsk, the Radium Hospital Foundation and other regional funds, as well as company contributions received so far from Roche, Novartis, Eli Lilly, Incyte and collaboration projects with Roche Foundation Medicine and Illumina. The Norwegian Medicines Agency represented by Marit Hystad participates in CONNECT as an observer.

Author information

Authors and Affiliations




K.T. wrote the manuscript and integrated edits from other authors. Important discussions and contributions to the initiatives described were made by all authors. All authors have approved the final version of the text.

Corresponding author

Correspondence to Kjetil Taskén.

Ethics declarations

Competing interests

Participation in the CONNECT Public–Private Partnership is regulated by a consortium agreement that handles conflicts of interest and regulates interaction with the publicly funded infrastructure InPreD-Norway and the investigator-initiated and publicly funded trial IMPRESS-Norway. IMPRESS-Norway (principal investigator Å.H.) has company contributions from Roche, Novartis, Incyte and Eli Lilly and collaboration projects with Roche Foundation Medicine and Illumina, regulated by separate agreements with Oslo University Hospital as the coordinating institution. The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taskén, K., Russnes, H.E.G., Aas, E. et al. A national precision cancer medicine implementation initiative for Norway. Nat Med 28, 885–887 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer